John E. Godwin

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia”.

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Blood(2020)10.1182/blood.2020007732

N/A

4.0DataRank · unranked

322 citations

Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt, Anjali S. Advani +43 more

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

Blood Advances(2020)10.1182/bloodadvances.2020002512

N/A

3.8DataRank · unranked

155 citations

Catherine Lai, Stephen Reeder, S. Church, Tressa Hood, Anbarasu Lourdusamy +24 more

A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers

Cancer(2024)10.1002/cncr.35200

N/A

0.612DataRank · unranked

12 citations

James Moon, Christopher D. Lao, Bartosz Chmielowski, Kari Kendra, Karl D. Lewis +12 more

Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia

Scientific Reports(2020)10.1038/s41598-020-62345-9

N/A

0DataRank · unranked

4 citations

Shannon McDonough, Cheryl L. Willman, Eric R. Koegle, John E. Godwin, Stephen H. Petersdorf +8 more

AML Risk Stratification Models Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Research Square(2020)10.21203/rs.3.rs-24023/v1

N/A

0DataRank · unranked

3 citations

Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, I-Ming L. Chen +17 more